Results
5-fluorouracil and bevacizumab reduced heart weight: According
to the plan, the mice were randomly divided and male mice were used to
exclude possible confounding factors caused by gender or hormone
fluctuation. There was no statistical difference between the baseline
body weight of each group. On the 7th and 14th day after injection, the
body weight of the 5-fluorouracil + bevacizumab group was lower than
that of the control group, but there was no statistical difference
(P > 0.05). As figure 1, part I. After 7 and 14 days
of injection of 5-fluorouracil and bevacizumab, the hearts of mice were
washed and weighed, and the HWI (heart weight index) was calculated. On
the 7th and 14th day, the heart weight index of 5- fluorouracil +
bevacizumab group was obviously lower than that of the control group
(P < 0.05). As figure 1, part J.
5-fluorouracil and
bevacizumab increased ST offset and PR interval: On the 7th and 14th
day after the injection of chemotherapy, the limb-lead ECG was recorded.
The ST deviation increased on the 7th and 14th day, but there was no
statistical significance (P > 0.05).
The P-R interval of 5-fluorouracil
+ bevacizumab group was also longer on the 7th and 14th day, but there
was no statistical significance (P >0.05). There was
no significant difference in Q wave between the control group and the
5-fluorouracil + bevacizumab group on the 7th day after injection of the
drug. On the 14th day, it was lower than the control group, but there
was no statistical difference (P >0.05). The P-wave
amplitude, R-wave amplitude, T-wave amplitude, QRS interval, ST interval
and QT interval of 5-fluorouracil + bevacizumab group had no significant
difference compared with the control group (P>0.05). The heart rate of 5- fluorouracil + bevacizumab
group was lower than that of the control group on the 7th and 14th day
after injection, but there was no significant difference between the two
groups (P >0.05). As figure 1.